 |
|
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Gerardo Heiss, MD;
Robert Wallace, MD;
Garnet L. Anderson, PhD;
Aaron Aragaki, MS;
Shirley A. A. Beresford, PhD;
Robert Brzyski, MD;
Rowan T. Chlebowski, MD;
Margery Gass, MD;
Andrea LaCroix, PhD;
JoAnn E. Manson, MD;
Ross L. Prentice, PhD;
Jacques Rossouw, MD;
Marcia L. Stefanick, PhD; for the WHI Investigators
JAMA. 2008;299(9):1036-1045.
Context The Women's Health Initiative (WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits.
Objective To report health outcomes at 3 years (mean 2.4 years of follow-up) after the intervention was stopped.
Design, Setting, and Participants The intervention phase was a double-blind, placebo-controlled, randomized trial of conjugated equine estrogens (CEE) 0.625 mg daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily, in 16 608 women aged 50 through 79 years, recruited by 40 centers from 1993 to 1998. The postintervention phase commenced July 8, 2002, and included 15 730 women.
Main Outcome Measures Semi-annual monitoring and outcomes ascertainment continued per trial protocol. The primary end points were coronary heart disease and invasive breast cancer. A global index summarizing the balance of risks and benefits included the 2 primary end points plus stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, and death due to other causes.
Results The risk of cardiovascular events after the intervention was comparable by initial randomized assignments, 1.97% (annualized rate) in the CEE plus MPA (343 events) and 1.91% in the placebo group (323 events). A greater risk of malignancies occurred in the CEE plus MPA than in the placebo group (1.56% [n = 281] vs 1.26% [n = 218]; hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.04-1.48). More breast cancers were diagnosed in women who had been randomly assigned to receive CEE plus MPA vs placebo (0.42% [n = 79] vs 0.33% [n = 60]; HR, 1.27; 95% CI, 0.91-1.78) with a modest trend toward a lower HR during the follow-up after the intervention. All-cause mortality was somewhat higher in the CEE plus MPA than in the placebo group (1.20% [n = 233] vs 1.06% [n = 196]; HR, 1.15; 95% CI, 0.95-1.39). The global index of risks and benefits was unchanged from randomization through March 31, 2005 (HR, 1.12; 95% CI, 1.03-1.21), indicating that the risks of CEE plus MPA exceed the benefits for chronic disease prevention.
Conclusions The increased cardiovascular risks in the women assigned to CEE plus MPA during the intervention period were not observed after the intervention. A greater risk of fatal and nonfatal malignancies occurred after the intervention in the CEE plus MPA group and the global risk index was 12% higher in women randomly assigned to receive CEE plus MPA compared with placebo.
Trial Registration clinicaltrials.gov Identifier: NCT00000611
Author Affiliations: University of North Carolina, Chapel Hill (Dr Heiss); University of Iowa, Iowa City (Dr Wallace); Fred Hutchinson Cancer Research Center, Seattle, Washington (Drs Anderson, Beresford, LaCroix, Prentice, and Mr Aragaki); University of Texas Health Science Center, San Antonio (Dr Brzyski); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California (Dr Chlebowski); University of Cincinnati, Cincinnati, Ohio (Dr Gass); Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Manson); National Heart, Lung, and Blood Institute, Bethesda, Maryland (Dr Rossouw); and Stanford Prevention Research Center, Stanford, California (Dr Stefanick).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Colorectal Cancer in Women After Stopping Postmenopausal Hormone Therapy
Timothy W. Odell
JAMA. 2008;299(23):2744.
EXTRACT
| FULL TEXT
Colorectal Cancer in Women After Stopping Postmenopausal Hormone Therapy—Reply
Rowan T. Chlebowski
JAMA. 2008;299(23):2744-2745.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Mammographic Screening and Risk Factors for Breast Cancer
Cook et al.
Am J Epidemiol 2009;170:1422-1432.
ABSTRACT
| FULL TEXT
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores
Hippisley-Cox and Coupland
BMJ 2009;339:b4229-b4229.
ABSTRACT
| FULL TEXT
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk
Reding et al.
Am J Epidemiol 2009;170:1241-1249.
ABSTRACT
| FULL TEXT
Spontaneous Regression of Breast Cancer
Richards
Arch Intern Med 2009;169:996-996.
FULL TEXT
Colorectal Cancer in Relation to Postmenopausal Estrogen and Estrogen Plus Progestin in the Women's Health Initiative Clinical Trial and Observational Study
Prentice et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1531-1537.
ABSTRACT
| FULL TEXT
Estimating the Impact of the Discontinuation of Medical Interventions on Health Outcomes
Weiss
Am J Epidemiol 2009;169:653-656.
ABSTRACT
| FULL TEXT
Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK
Lekander et al.
Menopause Int 2009;15:19-25.
ABSTRACT
| FULL TEXT
Prevention, Diagnosis, and Management of Osteoporosis-Related Fracture
Fakih
JAOA: Journal of the American Osteopathic Association 2009;109:191-193.
FULL TEXT
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski et al.
NEJM 2009;360:573-587.
ABSTRACT
| FULL TEXT
Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions
Kleinberg et al.
Endocr. Rev. 2009;30:51-74.
ABSTRACT
| FULL TEXT
Women's Issues in Pulmonary Medicine
Levine
ACCP Pulmonary Med Brd Rev 2009;25:705-722.
FULL TEXT
Commentary: The Year in Basic Science: Update of Estrogen Plus Progestin Therapy for Menopausal Hormone Replacement Implicating Stem Cells in the Increased Breast Cancer Risk
Horwitz
Mol. Endocrinol. 2008;22:2743-2750.
ABSTRACT
| FULL TEXT
Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
Mahoney et al.
CA Cancer J Clin 2008;0:CA.2008.0016v1-CA.2008.0016.
ABSTRACT
| FULL TEXT
Tibolone and the Promise of Ideal Hormone-Replacement Therapy
El-Hajj Fuleihan
NEJM 2008;359:753-755.
FULL TEXT
Update on Hormone Therapy: Evidence-Based Approaches
JWatch Women's Health 2008;2008:1-1.
FULL TEXT
Management of breast cancer--Part I
Turner and Jones
BMJ 2008;337:a421-a421.
FULL TEXT
Update in Female Reproduction: A Life-Cycle Approach
Barbieri
J. Clin. Endocrinol. Metab. 2008;93:2439-2446.
ABSTRACT
| FULL TEXT
Colorectal Cancer in Women After Stopping Postmenopausal Hormone Therapy
Odell
JAMA 2008;299:2744-2744.
FULL TEXT
Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond
Linet
Am J Epidemiol 2008;167:1416-1420.
ABSTRACT
| FULL TEXT
HABITS trial results confirmed in two-year follow-up
Brown
Menopause Int 2008;14:48-51.
FULL TEXT
Type of hormone replacement therapy and risk of venous thromboembolism
Roberts
BMJ 2008;336:1203-1204.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;336:582-583.
FULL TEXT
What Happened to WHI Patients Who Stopped Taking Estrogen and Progestin?
JWatch General 2008;2008:1-1.
FULL TEXT
WHI Estrogen-Plus-Progestin Trial: 3 Years Later
JWatch Women's Health 2008;2008:1-1.
FULL TEXT
|
